{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:14:08Z","timestamp":1791872048509,"version":"4.3.4"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The parasite\n                    <jats:italic>Cryptosporidium<\/jats:italic>\n                    is a leading cause of life-threatening diarrhoeal disease, and effective treatment is not available. Clofazimine, an antimicrobial used for treatment of leprosy and tuberculosis, was found to have potent anti-\n                    <jats:italic>Cryptosporidium<\/jats:italic>\n                    activity but it failed in a human trial. This was attributed to poor bioavailability. Here we observed differential clofazimine susceptibility among\n                    <jats:italic>C. parvum<\/jats:italic>\n                    parasite isolates, which we exploit to identify a single genomic locus encoding the type II NADH dehydrogenase (NDH2) in an unbiased genetic cross. Targeted genetic ablation of\n                    <jats:italic>ndh2<\/jats:italic>\n                    resulted in high-level clofazimine resistance and biochemical studies demonstrated NDH2-mediated electron transfer to clofazimine. Through genomic analyses, we uncovered heterogeneity at the\n                    <jats:italic>ndh2<\/jats:italic>\n                    locus for\n                    <jats:italic>C. parvum<\/jats:italic>\n                    and\n                    <jats:italic>C. hominis<\/jats:italic>\n                    , and widespread carriage of a conserved attenuated allele across multiple continents. This heterogeneity allows parasites genomically linked through frequent sexual recombination to adjust to changing NDH2 requirements and predisposes\n                    <jats:italic>Cryptosporidium<\/jats:italic>\n                    to evade clofazimine treatment.\n                  <\/jats:p>","DOI":"10.1038\/s41564-026-02331-5","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:07:49Z","timestamp":1778663269000},"page":"1559-1572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Genomic heterogeneity of NAD(P)H dehydrogenase predisposes Cryptosporidium to clofazimine resistance"],"prefix":"10.1038","volume":"11","author":[{"given":"Gracyn Y.","family":"Buenconsejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7163-5650","authenticated-orcid":false,"given":"Sebastian","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9934-6404","authenticated-orcid":false,"given":"Aur\u00e9lia C.","family":"Balestra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9278-0697","authenticated-orcid":false,"given":"Keenan M.","family":"O\u2019Dea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-0659","authenticated-orcid":false,"given":"Guan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Beiting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-432X","authenticated-orcid":false,"given":"Boris","family":"Striepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"2331_CR1","first-page":"589","volume":"31","author":"Centers for Disease Control (CDC).","year":"1982","unstructured":"Centers for Disease Control (CDC). Cryptosporidiosis: assessment of chemotherapy of males with acquired immune deficiency syndrome (AIDS). MMWR Morb. Mortal. Wkly Rep. 31, 589\u2013592 (1982).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"2331_CR2","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.4049\/jimmunol.2200512","volume":"209","author":"IS Cohn","year":"2022","unstructured":"Cohn, I. S., Henrickson, S. E., Striepen, B. & Hunter, C. A. Immunity to Cryptosporidium: lessons from acquired and primary immunodeficiencies. J. Immunol. 209, 2261\u20132268 (2022).","journal-title":"J. Immunol."},{"key":"2331_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1473-3099(14)70772-8","volume":"15","author":"W Checkley","year":"2015","unstructured":"Checkley, W. et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for Cryptosporidium. Lancet Infect. Dis. 15, 85\u201394 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"2331_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","volume":"382","author":"KL Kotloff","year":"2013","unstructured":"Kotloff, K. L. et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382, 209\u2013222 (2013).","journal-title":"Lancet"},{"key":"2331_CR5","doi-asserted-by":"publisher","first-page":"e758","DOI":"10.1016\/S2214-109X(18)30283-3","volume":"6","author":"IA Khalil","year":"2018","unstructured":"Khalil, I. A. et al. Morbidity, mortality, and long-term consequences associated with diarrhoea from Cryptosporidium infection in children younger than 5 years: a meta-analyses study. Lancet Glob. Health 6, e758\u2013e768 (2018).","journal-title":"Lancet Glob. Health"},{"key":"2331_CR6","doi-asserted-by":"crossref","unstructured":"Gilbert, I. H. et al. Safe and effective treatments are needed for cryptosporidiosis, a truly neglected tropical disease. BMJ Glob. Health 8, e012540 (2023).","DOI":"10.1136\/bmjgh-2023-012540"},{"key":"2331_CR7","doi-asserted-by":"publisher","first-page":"e0003987","DOI":"10.1371\/journal.pntd.0003987","volume":"9","author":"CD Huston","year":"2015","unstructured":"Huston, C. D. et al. A proposed target product profile and developmental cascade for new cryptosporidiosis treatments. PLoS Negl. Trop. Dis. 9, e0003987 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2331_CR8","doi-asserted-by":"crossref","unstructured":"Ashigbie, P. G. et al. Use-case scenarios for an anti-Cryptosporidium therapeutic. PLoS Neglect. Trop. Dis. 15, e0009057 (2021).","DOI":"10.1371\/journal.pntd.0009057"},{"key":"2331_CR9","doi-asserted-by":"crossref","unstructured":"Love, M. S. & Choy, R. K. M. Emerging treatment options for cryptosporidiosis. Curr. Opin. Infect. Dis. 34, 455\u2013462 (2021).","DOI":"10.1097\/QCO.0000000000000761"},{"key":"2331_CR10","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1128\/AAC.02460-12","volume":"57","author":"K Bessoff","year":"2013","unstructured":"Bessoff, K., Sateriale, A., Lee, K. K. & Huston, C. D. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth. Antimicrob. Agents Chemother. 57, 1804\u20131814 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2331_CR11","doi-asserted-by":"publisher","first-page":"e0005373","DOI":"10.1371\/journal.pntd.0005373","volume":"11","author":"MS Love","year":"2017","unstructured":"Love, M. S. et al. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. PLoS Negl. Trop. Dis. 11, e0005373 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2331_CR12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature22337","volume":"546","author":"UH Manjunatha","year":"2017","unstructured":"Manjunatha, U. H. et al. A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis. Nature 546, 376\u2013380 (2017).","journal-title":"Nature"},{"key":"2331_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115539","volume":"167","author":"J Xu","year":"2023","unstructured":"Xu, J., Koval, A. & Katanaev, V. L. Clofazimine: a journey of a drug. Biomed. Pharmacother. 167, 115539 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"2331_CR14","unstructured":"Chemotherapy of leprosy for control programmes. World Health Organ. Tech. Rep. Ser. 675, 1\u201333 (1982)."},{"key":"2331_CR15","unstructured":"Guglielmetti, L. et al. Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial. Lancet Respir. Med. 13, 809\u2013820 (2025)."},{"key":"2331_CR16","unstructured":"World Health Organization: Key updates to the treatment of drug-resistant tuberculosis: rapid communication, June 2024 (World Health Organization, 2024)."},{"key":"2331_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1100488","volume":"14","author":"JAM Stadler","year":"2023","unstructured":"Stadler, J. A. M., Maartens, G., Meintjes, G. & Wasserman, S. Clofazimine for the treatment of tuberculosis. Front. Pharmacol. 14, 1100488 (2023).","journal-title":"Front. Pharmacol."},{"key":"2331_CR18","first-page":"133","volume":"44","author":"NE Morrison","year":"1976","unstructured":"Morrison, N. E. & Marley, G. M. The mode of action of clofazimine DNA binding studies. Int. J. Lepr. Other Mycobact. Dis. 44, 133\u2013134 (1976).","journal-title":"Int. J. Lepr. Other Mycobact. Dis."},{"key":"2331_CR19","doi-asserted-by":"publisher","first-page":"10276","DOI":"10.1074\/jbc.M110.200501","volume":"286","author":"T Yano","year":"2011","unstructured":"Yano, T. et al. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J. Biol. Chem. 286, 10276\u201310287 (2011).","journal-title":"J. Biol. Chem."},{"key":"2331_CR20","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1128\/AAC.00395-15","volume":"59","author":"B Lechartier","year":"2015","unstructured":"Lechartier, B. & Cole, S. T. Mode of action of clofazimine and combination therapy with benzothiazinones against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 59, 4457\u20134463 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2331_CR21","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1128\/AAC.36.12.2729","volume":"36","author":"CE Van Rensburg","year":"1992","unstructured":"Van Rensburg, C. E., Joone, G. K., O\u2019Sullivan, J. F. & Anderson, R. Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids. Antimicrob. Agents Chemother. 36, 2729\u20132735 (1992).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2331_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/jac\/44.2.209","volume":"44","author":"HC Steel","year":"1999","unstructured":"Steel, H. C., Matlola, N. M. & Anderson, R. Inhibition of potassium transport and growth of mycobacteria exposed to clofazimine and B669 is associated with a calcium-independent increase in microbial phospholipase A2 activity. J. Antimicrob. Chemother. 44, 209\u2013216 (1999).","journal-title":"J. Antimicrob. Chemother."},{"key":"2331_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/jac\/38.3.349","volume":"38","author":"EE De Bruyn","year":"1996","unstructured":"De Bruyn, E. E., Steel, H. C., Van Rensburg, E. J. & Anderson, R. The riminophenazines, clofazimine and B669, inhibit potassium transport in Gram-positive bacteria by a lysophospholipid-dependent mechanism. J. Antimicrob. Chemother. 38, 349\u2013362 (1996).","journal-title":"J. Antimicrob. Chemother."},{"key":"2331_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/cid\/ciaa421","volume":"73","author":"P Iroh Tam","year":"2021","unstructured":"Iroh Tam, P. et al. Clofazimine for treatment of cryptosporidiosis in human immunodeficiency virus infected adults: an experimental medicine, randomized, double-blind, placebo-controlled phase 2a trial. Clin. Infect. Dis. 73, 183\u2013191 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"2331_CR25","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/psp4.13092","volume":"13","author":"CX Zhang","year":"2024","unstructured":"Zhang, C. X. et al. Clofazimine pharmacokinetics in HIV-infected adults with diarrhea: implications of diarrheal disease on absorption of orally administered therapeutics. CPT Pharmacometrics Syst. Pharmacol. 13, 410\u2013423 (2024).","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"2331_CR26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01560-21","volume":"66","author":"CX Zhang","year":"2022","unstructured":"Zhang, C. X. et al. Pharmacokinetics and pharmacodynamics of clofazimine for treatment of cryptosporidiosis. Antimicrob. Agents Chemother. 66, e0156021 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2331_CR27","doi-asserted-by":"publisher","first-page":"eaax7161","DOI":"10.1126\/scitranslmed.aax7161","volume":"11","author":"C Swale","year":"2019","unstructured":"Swale, C. et al. Metal-captured inhibition of pre-mRNA processing activity by CPSF3 controls Cryptosporidium infection. Sci. Transl. Med. 11, eaax7161 (2019).","journal-title":"Sci. Transl. Med."},{"key":"2331_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116315","volume":"44","author":"S Shaw","year":"2025","unstructured":"Shaw, S. et al. Genetic crosses reveal genomic loci responsible for virulence in Cryptosporidium parvum infection. Cell Rep. 44, 116315 (2025).","journal-title":"Cell Rep."},{"key":"2331_CR29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature14651","volume":"523","author":"S Vinayak","year":"2015","unstructured":"Vinayak, S. et al. Genetic modification of the diarrhoeal pathogen Cryptosporidium parvum. Nature 523, 477\u2013480 (2015).","journal-title":"Nature"},{"key":"2331_CR30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2313210120","volume":"121","author":"S Shaw","year":"2024","unstructured":"Shaw, S. et al. Genetic crosses within and between species of Cryptosporidium. Proc. Natl Acad. Sci. USA 121, e2313210120 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2331_CR31","doi-asserted-by":"crossref","unstructured":"Vinayak, S. et al. Bicyclic azetidines kill the diarrheal pathogen Cryptosporidium in mice by inhibiting parasite phenylalanyl-tRNA synthetase. Sci. Transl. Med. 12, eaba8412 (2020).","DOI":"10.1126\/scitranslmed.aba8412"},{"key":"2331_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-025-05364-3","volume":"12","author":"RP Baptista","year":"2025","unstructured":"Baptista, R. P., Xiao, R., Li, Y., Glenn, T. C. & Kissinger, J. C. New T2T assembly of Cryptosporidium parvum IOWA II annotated with legacy-compatible gene identifiers. Sci. Data 12, 1039 (2025).","journal-title":"Sci. Data"},{"key":"2331_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.parint.2022.102653","volume":"91","author":"X Li","year":"2022","unstructured":"Li, X., Kumar, S., Brenneman, K. V. & Anderson, T. J. C. Bulk segregant linkage mapping for rodent and human malaria parasites. Parasitol. Int. 91, 102653 (2022).","journal-title":"Parasitol. Int."},{"key":"2331_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41420-023-01352-x","volume":"9","author":"Y Cen","year":"2023","unstructured":"Cen, Y. et al. Novel roles of RNA-binding proteins in drug resistance of breast cancer: from molecular biology to targeting therapeutics. Cell Death Discov. 9, 52 (2023).","journal-title":"Cell Death Discov."},{"key":"2331_CR35","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1021\/acsinfecdis.7b00275","volume":"4","author":"D Murugesan","year":"2018","unstructured":"Murugesan, D. et al. 2-mercapto-quinazolinones as inhibitors of type II NADH dehydrogenase and Mycobacterium tuberculosis: structure\u2013activity relationships, mechanism of action and absorption, distribution, metabolism, and excretion characterization. ACS Infect. Dis. 4, 954\u2013969 (2018).","journal-title":"ACS Infect. Dis."},{"key":"2331_CR36","doi-asserted-by":"crossref","unstructured":"Nies, S. C. et al. Systems analysis of NADH dehydrogenase mutants reveals flexibility and limits of Pseudomonas taiwanensis VLB120\u2019s metabolism. Appl. Environ. Microbiol. 86, e03038-19 (2020).","DOI":"10.1128\/AEM.03038-19"},{"key":"2331_CR37","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1021\/ml300134b","volume":"3","author":"PS Shirude","year":"2012","unstructured":"Shirude, P. S. et al. Quinolinyl pyrimidines: potent inhibitors of NDH-2 as a novel class of anti-TB agents. ACS Med. Chem. Lett. 3, 736\u2013740 (2012).","journal-title":"ACS Med. Chem. Lett."},{"key":"2331_CR38","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1021\/bi100005j","volume":"49","author":"M Murai","year":"2010","unstructured":"Murai, M. et al. Characterization of the ubiquinone binding site in the alternative NADH-quinone oxidoreductase of Saccharomyces cerevisiae by photoaffinity labeling. Biochemistry 49, 2973\u20132980 (2010).","journal-title":"Biochemistry"},{"key":"2331_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/srep40165","volume":"7","author":"JN Blaza","year":"2017","unstructured":"Blaza, J. N. et al. The mechanism of catalysis by type-II NADH:quinone oxidoreductases. Sci. Rep. 7, 40165 (2017).","journal-title":"Sci. Rep."},{"key":"2331_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-016-3343-5","volume":"17","author":"S Liu","year":"2016","unstructured":"Liu, S. et al. Evolution of mitosome metabolism and invasion-related proteins in Cryptosporidium. BMC Genomics 17, 1006 (2016).","journal-title":"BMC Genomics"},{"key":"2331_CR41","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s00294-003-0432-1","volume":"44","author":"CE Riordan","year":"2003","unstructured":"Riordan, C. E., Ault, J. G., Langreth, S. G. & Keithly, J. S. Cryptosporidium parvum Cpn60 targets a relict organelle. Curr. Genet. 44, 138\u2013147 (2003).","journal-title":"Curr. Genet."},{"key":"2331_CR42","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/BF00931092","volume":"76","author":"K Ostrovska","year":"1990","unstructured":"Ostrovska, K. & Paperna, I. Cryptosporidium sp. of the starred lizard Agame stellio: ultrastructure and life cycle. Parasitol. Res. 76, 712\u2013720 (1990).","journal-title":"Parasitol. Res."},{"key":"2331_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.molbiopara.2004.05.007","volume":"137","author":"MJ Gubbels","year":"2004","unstructured":"Gubbels, M. J., Wieffer, M. & Striepen, B. Fluorescent protein tagging in Toxoplasma gondii: identification of a novel inner membrane complex component conserved among Apicomplexa. Mol. Biochem. Parasitol. 137, 99\u2013110 (2004).","journal-title":"Mol. Biochem. Parasitol."},{"key":"2331_CR44","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/molbev\/msn070","volume":"25","author":"SB Gould","year":"2008","unstructured":"Gould, S. B., Tham, W. H., Cowman, A. F., McFadden, G. I. & Waller, R. F. Alveolins, a new family of cortical proteins that define the protist infrakingdom Alveolata. Mol. Biol. Evol. 25, 1219\u20131230 (2008).","journal-title":"Mol. Biol. Evol."},{"key":"2331_CR45","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.parint.2010.04.005","volume":"59","author":"T Mogi","year":"2010","unstructured":"Mogi, T. & Kita, K. Diversity in mitochondrial metabolic pathways in parasitic protists Plasmodium and Cryptosporidium. Parasitol. Int. 59, 305\u2013312 (2010).","journal-title":"Parasitol. Int."},{"key":"2331_CR46","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202501254R","volume":"39","author":"N Li","year":"2025","unstructured":"Li, N. et al. Biological characterization of alternative oxidase in Cryptosporidium mitosome. FASEB J. 39, e71000 (2025).","journal-title":"FASEB J."},{"key":"2331_CR47","first-page":"e01120","volume":"0","author":"S Deng","year":"2025","unstructured":"Deng, S., Beatty, W. & Sibley, L. D. Assessing the function of the alternative electron transport chain in the Cryptosporidium parvum mitosome. mBio 0, e01120\u2013e01125 (2025).","journal-title":"mBio"},{"key":"2331_CR48","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.1073\/pnas.1814685116","volume":"116","author":"B Baragana","year":"2019","unstructured":"Baragana, B. et al. Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. Proc. Natl Acad. Sci. USA 116, 7015\u20137020 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2331_CR49","doi-asserted-by":"crossref","unstructured":"Lee, S. et al. Piperazine-derivative MMV665917: an effective drug in the diarrheic piglet model of Cryptosporidium hominis. J. Infect. Dis. 220, 285\u2013293 (2019).","DOI":"10.1093\/infdis\/jiz105"},{"key":"2331_CR50","doi-asserted-by":"crossref","unstructured":"Jumani, R. S. et al. A Novel piperazine-based drug lead for cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box. Antimicrob. Agents Chemother. 62, e01505-17 (2018).","DOI":"10.1128\/AAC.01505-17"},{"key":"2331_CR51","doi-asserted-by":"publisher","first-page":"e591","DOI":"10.1016\/S1473-3099(24)00141-5","volume":"24","author":"PJ Rosenthal","year":"2024","unstructured":"Rosenthal, P. J. et al. The emergence of artemisinin partial resistance in Africa: how do we respond? Lancet Infect. Dis. 24, e591\u2013e600 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"2331_CR52","doi-asserted-by":"crossref","unstructured":"Hasan, M. M. et al. Spontaneous selection of Cryptosporidium drug resistance in a calf model of infection. Antimicrob. Agents Chemother. 65, e00023-21 (2021).","DOI":"10.1128\/AAC.00023-21"},{"key":"2331_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12956-2","volume":"10","author":"T Beites","year":"2019","unstructured":"Beites, T. et al. Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development. Nat. Commun. 10, 4970 (2019).","journal-title":"Nat. Commun."},{"key":"2331_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2025.103782","volume":"114","author":"HP Kandagatla","year":"2025","unstructured":"Kandagatla, H. P. et al. Highly increasing solubility of clofazimine, an extremely water-insoluble basic drug, in lipid-based SEDDS using digestion products of long-chain lipids. J. Pharm. Sci. 114, 103782 (2025).","journal-title":"J. Pharm. Sci."},{"key":"2331_CR55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ejpb.2023.04.009","volume":"187","author":"K Yamanouchi","year":"2023","unstructured":"Yamanouchi, K. et al. Improvement and characterization of oral absorption behavior of clofazimine by SNEDDS: quantitative evaluation of extensive lymphatic transport. Eur. J. Pharm. Biopharm. 187, 141\u2013155 (2023).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2331_CR56","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-micro-032421-120540","volume":"77","author":"IM Lamb","year":"2023","unstructured":"Lamb, I. M., Okoye, I. C., Mather, M. W. & Vaidya, A. B. Unique properties of apicomplexan mitochondria. Annu. Rev. Microbiol. 77, 541\u2013560 (2023).","journal-title":"Annu. Rev. Microbiol."},{"key":"2331_CR57","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2958.2011.07807.x","volume":"82","author":"SS Lin","year":"2011","unstructured":"Lin, S. S., Gross, U. & Bohne, W. Two internal type II NADH dehydrogenases of Toxoplasma gondii are both required for optimal tachyzoite growth. Mol. Microbiol. 82, 209\u2013221 (2011).","journal-title":"Mol. Microbiol."},{"key":"2331_CR58","doi-asserted-by":"publisher","first-page":"32661","DOI":"10.1074\/jbc.M111.269399","volume":"286","author":"KE Boysen","year":"2011","unstructured":"Boysen, K. E. & Matuschewski, K. Arrested oocyst maturation in Plasmodium parasites lacking type II NADH:ubiquinone dehydrogenase. J. Biol. Chem. 286, 32661\u201332671 (2011).","journal-title":"J. Biol. Chem."},{"key":"2331_CR59","doi-asserted-by":"publisher","first-page":"e0214023","DOI":"10.1371\/journal.pone.0214023","volume":"14","author":"H Ke","year":"2019","unstructured":"Ke, H. et al. Mitochondrial type II NADH dehydrogenase of Plasmodium falciparum (PfNDH2) is dispensable in the asexual blood stages. PLoS ONE 14, e0214023 (2019).","journal-title":"PLoS ONE"},{"key":"2331_CR60","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.chom.2023.03.001","volume":"31","author":"A Guerin","year":"2023","unstructured":"Guerin, A. et al. Cryptosporidium uses multiple distinct secretory organelles to interact with and modify its host cell. Cell Host Microbe 31, 650\u2013664.e6 (2023).","journal-title":"Cell Host Microbe"},{"key":"2331_CR61","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00022-23","volume":"91","author":"HB Smith","year":"2023","unstructured":"Smith, H. B. et al. Listeria monocytogenes requires DHNA-dependent intracellular redox homeostasis facilitated by Ndh2 for survival and virulence. Infect. Immun. 91, e0002223 (2023).","journal-title":"Infect. Immun."},{"key":"2331_CR62","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/j.chom.2023.11.008","volume":"31","author":"MR Maradana","year":"2023","unstructured":"Maradana, M. R. et al. Dietary environmental factors shape the immune defense against Cryptosporidium infection. Cell Host Microbe 31, 2038\u20132050.e4 (2023).","journal-title":"Cell Host Microbe"},{"key":"2331_CR63","doi-asserted-by":"crossref","unstructured":"Marzook, N. B. et al. The essential host genome for Cryptosporidium survival exposes metabolic dependencies that can be leveraged for treatment. Cell 188, 5947\u20135961.e15 (2025).","DOI":"10.1016\/j.cell.2025.07.001"},{"key":"2331_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112680","volume":"42","author":"LJ Funkhouser-Jones","year":"2023","unstructured":"Funkhouser-Jones, L. J. et al. Microbiota-produced indole metabolites disrupt mitochondrial function and inhibit Cryptosporidium parvum growth. Cell Rep. 42, 112680 (2023).","journal-title":"Cell Rep."},{"key":"2331_CR65","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.chom.2025.07.024","volume":"33","author":"W Huang","year":"2025","unstructured":"Huang, W. et al. Cryptosporidium parvum multidrug resistance protein confers resistance to toxic gut microbial metabolite. Cell Host Microbe 33, 1589\u20131605.e9 (2025).","journal-title":"Cell Host Microbe"},{"key":"2331_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbabio.2024.149529","volume":"1866","author":"DV Gospodaryov","year":"2025","unstructured":"Gospodaryov, D. V. Alternative NADH dehydrogenase: a complex I backup, a drug target, and a tool for mitochondrial gene therapy. Biochim. Biophys. Acta Bioenerg. 1866, 149529 (2025).","journal-title":"Biochim. Biophys. Acta Bioenerg."},{"key":"2331_CR67","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.immuni.2025.07.012","volume":"58","author":"SE Weinberg","year":"2025","unstructured":"Weinberg, S. E. & Chandel, N. S. Mitochondria reactive oxygen species signaling-dependent immune responses in macrophages and T cells. Immunity 58, 1904\u20131921 (2025).","journal-title":"Immunity"},{"key":"2331_CR68","doi-asserted-by":"publisher","first-page":"e1000214","DOI":"10.1371\/journal.ppat.1000214","volume":"4","author":"K Ganesan","year":"2008","unstructured":"Ganesan, K. et al. A genetically hard-wired metabolic transcriptome in Plasmodium falciparum fails to mount protective responses to lethal antifolates. PLoS Pathog. 4, e1000214 (2008).","journal-title":"PLoS Pathog."},{"key":"2331_CR69","doi-asserted-by":"crossref","unstructured":"Walzer, K. A. et al. Transcriptional control of the Cryptosporidium life cycle. Nature 630, 174\u2013180 (2024).","DOI":"10.1038\/s41586-024-07466-1"},{"key":"2331_CR70","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1038\/s41564-019-0539-x","volume":"4","author":"J Tandel","year":"2019","unstructured":"Tandel, J. et al. Life cycle progression and sexual development of the apicomplexan parasite Cryptosporidium parvum. Nat. Microbiol. 4, 2226\u20132236 (2019).","journal-title":"Nat. Microbiol."},{"key":"2331_CR71","doi-asserted-by":"publisher","first-page":"e3001604","DOI":"10.1371\/journal.pbio.3001604","volume":"20","author":"ED English","year":"2022","unstructured":"English, E. D., Guerin, A., Tandel, J. & Striepen, B. Live imaging of the Cryptosporidium parvum life cycle reveals direct development of male and female gametes from type I meronts. PLoS Biol. 20, e3001604 (2022).","journal-title":"PLoS Biol."},{"key":"2331_CR72","unstructured":"Shaw, S. et al. Cryptosporidium. Methods in Molecular Biology 2 edn, Vol. 2978 (Humana Press, 2025)."},{"key":"2331_CR73","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"2331_CR74","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"2331_CR75","doi-asserted-by":"crossref","unstructured":"Mansfeld, B. N. & Grumet, R. QTLseqr: an R package for bulk segregant analysis with next-generation sequencing. Plant Genome 11, 180006 (2018).","DOI":"10.3835\/plantgenome2018.01.0006"},{"key":"2331_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-024-04235-7","volume":"11","author":"LR Penumarthi","year":"2024","unstructured":"Penumarthi, L. R., Baptista, R. P., Beaudry, M. S., Glenn, T. C. & Kissinger, J. C. A new chromosome-level genome assembly and annotation of Cryptosporidium meleagridis. Sci. Data 11, 1388 (2024).","journal-title":"Sci. Data"},{"key":"2331_CR77","unstructured":"Xiao, R., Shaw, S., Buenconsejo, G. Y. cparvum_ndh2_clofazimine-resistance. GitHub https:\/\/github.com\/ruicatxiao\/cparvum_ndh2_clofazimine-resistance (2025)."}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02331-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02331-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02331-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:03:52Z","timestamp":1780585432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02331-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":77,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["2331"],"URL":"https:\/\/doi.org\/10.1038\/s41564-026-02331-5","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}